文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

母源GNAS等位基因失活突变患者甲状旁腺激素抵抗进行性发展

Progressive Development of PTH Resistance in Patients With Inactivating Mutations on the Maternal Allele of GNAS.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

该研究回顾性分析20例携带母源GNAS突变的iPPSD2(PHP1A)患者,诊断平均年龄3.9岁,平均随访2年。随访中PTH升高(179至306 pg/mL,P<0.05)、钙降低(2.31至2.21 mmol/L,P<0.05),磷酸盐未随年龄预期下降。作者认为甲状旁腺激素抵抗和低钙血症随时间发展,建议对异位骨化或家族史者筛查母源GNAS突变并定期监测钙、磷、PTH。

要点

  • 所有患者在诊断时即存在TSH抵抗(TSH 13.3±9.0 mIU/L)。
  • 随访中PTH升高、血钙降低,磷酸盐未随年龄预期下降。
  • 1例7月龄对PTH输注反应正常,4岁时反应受损。

核心结论

  • 在iPPSD2(PHP1A)患者中,甲状旁腺激素抵抗和低钙血症随时间发展。
  • 作者认为,即使无甲状旁腺激素抵抗和低钙血症,存在异位骨化或家族史时也应筛查母源GNAS突变。
  • 作者认为,这些患者的随访应包括定期评估钙、磷和PTH水平。

研究设计与样本

  • 回顾性研究,纳入20例经家族史、异位骨化或矮小诊断且携带GNAS突变的iPPSD2(PHP1A)患者。
  • 定期收集钙、磷酸盐、促甲状腺激素(TSH)和PTH水平的回顾性数据。
  • 对1例患者进行PTH输注试验(特立帕肽)。

主要发现

  • 患者诊断平均年龄3.9岁,平均随访2年。
  • 诊断时所有患者已存在TSH抵抗,TSH为13.3±9.0 mIU/L。
  • 随访中PTH水平升高(179至306 pg/mL;P<0.05),钙水平降低(2.31至2.21 mmol/L;P<0.05),磷酸盐水平未随年龄增长出现健康个体预期的下降。
  • 1例出生时即有异位骨化的患者,7月龄时PTH输注后环磷酸腺苷升高程度与对照相似,4岁时反应受损。

临床怎么用

  • 作者认为,存在异位骨化或家族史时,即使无甲状旁腺激素抵抗和低钙血症,也应筛查母源GNAS突变。
  • 作者认为,这些患者的随访应包括定期评估钙、磷和PTH水平。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Parathormone (PTH) resistance is characterized by hypocalcaemia, hyperphosphatemia, and elevated PTH in the absence of vitamin D deficiency. Pseudohypoparathyroidism type 1A [PHP1A, or inactivating parathormone (PTH)/PTHrp signaling disorder 2, according to the new classification (iPPSD2)], is caused by mutations in the maternal GNAS allele. OBJECTIVE: To assess PTH resistance over time in 20 patients affected by iPPSD2 (PHP1A), diagnosed because of family history, ectopic ossification, or short stature, and carrying a GNAS mutation. METHODS: We gathered retrospective data for calcium, phosphate, thyrotropin (TSH), and PTH levels at regular intervals. PTH infusion testing (teriparatide) was performed in 1 patient. RESULTS: Patients were diagnosed at a mean age of 3.9 years and had a mean follow-up of 2 years. TSH resistance was already present at diagnosis in all patients (TSH, 13.3 ± 9.0 mIU/L). Over time, PTH levels increased (179 to 306 pg/mL; P < 0.05), and calcium levels decreased (2.31 to 2.21 mmol/L; P < 0.05), but phosphate levels did not decrease with age as expected for healthy individuals. One patient born with ectopic ossifications showed an increase in cyclic adenosine monophosphate upon PTH infusion, similar to that of controls, at 7 months of age, but an impaired response at 4 years of age. CONCLUSIONS: In patients with iPPSD2 (PHP1A), PTH resistance and hypocalcemia develop over time. These findings highlight the importance of screening for maternal GNAS mutations in the presence of ectopic ossifications or family history, even in the absence of PTH resistance and hypocalcemia. The follow-up of these patients should include regular assessments of calcium, phosphate, and PTH levels.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Usardi A, Mamoune A, Nattes E, et al. Progressive Development of PTH Resistance in Patients With Inactivating Mutations on the Maternal Allele of GNAS. J Clin Endocrinol Metab. 2017. PMID: 28323910. doi:10.1210/jc.2016-3544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。